According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds, while those who took semaglutide, or Wegovy, lost about 33 pounds. The two weight-loss drugs are ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated and prescribed. Glass points out that obesity is a complex condition, and people with obesity often have other health issues as well, related to the heart, kidney, and liver. “It’s not just about weight,” he says.

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.

The best metric is not weight, but a particularly toxic kind of fat.

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement levels. The company most associated with obesity treatments, Denmark-based Novo Nordisk (NYSE: NVO),

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal regulators crack down on the